Multicentric carpotarsal osteolysis syndrome with variants of MAFB gene: a case report and literature review

Xianfei Gao,Xiang Fang,Danping Huang,Song Zhang,Huasong Zeng
DOI: https://doi.org/10.1186/s12969-024-00964-6
2024-03-15
Pediatric Rheumatology
Abstract:Multicentric carpotarsal osteolysis (MCTO) is a rare genetic disorder characterized by the progressive loss of bone in the hands, feet, and other skeletal structures. It presents with symptoms that may resemble those of juvenile idiopathic arthritis, making diagnosis challenging for clinicians. The identification of MAF BZIP Transcription Factor B (MAFB) mutations as significant contributors to MCTO represents a major breakthrough in our understanding of the pathogenesis of this rare skeletal disorder.
pediatrics,rheumatology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the diagnostic and treatment challenges of Multicentric Carpotarsal Osteolysis (MCTO). MCTO is a rare hereditary disease, mainly characterized by the progressive loss of bone in the hands, feet and other bone structures. This disease is easily confused with other similar diseases clinically, such as Juvenile Idiopathic Arthritis (JIA), which leads to difficulties in diagnosis. In addition, due to the rarity of MCTO, the current understanding of effective treatment methods for it is limited. Through a specific case report and literature review, the paper explores the following aspects: 1. **Clinical manifestations**: It details the clinical symptoms of a 4 - year - old boy, including polydactyly of fingers, pain and swelling in the wrists and hands, ulnar deviation, and swelling in the left ankle joint and metacarpophalangeal joints. 2. **Diagnostic methods**: It emphasizes the importance of early use of MRI examination and Whole Exome Sequencing (WES), which are helpful for early and accurate diagnosis of MCTO. 3. **Treatment regimens**: It introduces the situation of the patient receiving methotrexate, methylprednisolone and Denosumab treatment, especially the effect of Denosumab as a potential treatment drug. Overall, the paper aims to provide diagnostic and treatment experience of MCTO through specific case reports, in order to improve the recognition ability and treatment level of clinicians for this rare disease.